CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine

Better understanding of the biology of resistance to DNA methyltransferase (DNMT) inhibitors is required to identify therapies that can improve their efficacy for patients with high-risk myelodysplastic syndrome (MDS). CCRL2 is an atypical chemokine receptor that is upregulated in CD34(+) cells from...

Descripción completa

Detalles Bibliográficos
Autores principales: Karantanos, Theodoros, Teodorescu, Patric, Arvanitis, Marios, Perkins, Brandy, Jain, Tania, DeZern, Amy E., Dalton, W. Brian, Christodoulou, Ilias, Paun, Bogdan C., Varadhan, Ravi, Esteb, Christopher, Rajkhowa, Trivikram, Bonifant, Challice, Gondek, Lukasz P., Levis, Mark J., Yegnasubramanian, Srinivasan, Ghiaur, Gabriel, Jones, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Myelodysplastic Syndromes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316237/
https://www.ncbi.nlm.nih.gov/pubmed/36519323
http://dx.doi.org/10.3324/haematol.2022.281444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316237/
https://www.ncbi.nlm.nih.gov/pubmed/36519323
http://dx.doi.org/10.3324/haematol.2022.281444

Ejemplares similares